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ABBREVIATIONS
DIS Drooling Impact Scale
RCT Randomized controlled trial
AIM To compare the effect of bilateral submandibular duct ligation and botulinum
neurotoxin A (BoNT-A) on drooling severity and its impact on daily life and care in children
and adolescents with moderate-to-severe drooling.
METHOD This was a randomized, interventional, controlled trial in which 53 children and
adolescents (31 males, 22 females, mean age 11y, range 8–22y, SD 2y 10mo) with cerebral
palsy (58.5%) or other non-progressive developmental disorders (41.5%) were randomized to
BoNT-A (n=26) or bilateral submandibular duct ligation (n=27). A parent questionnaire on the
severity of drooling in specific positions and daily activities and the impact of drooling on
daily life and care was filled out at baseline and 8 and 32 weeks posttreatment.
RESULTS Both BoNT-A and bilateral submandibular duct ligation had a positive effect on
daily care, damage to electronic equipment and/or furniture, social interactions, and self-
esteem. However, bilateral submandibular duct ligation had a significant greater and longer-
lasting short- (8wks) and medium-term (32wks) effect on daily care, reducing damage to
electronic devices, and improving social interactions and satisfaction with life in general.
INTERPRETATION This randomized controlled trial confirms reduced drooling by both BoNT-A
and bilateral submandibular duct ligation, but provides new evidence on improved well-
being through a reduction in drooling. Even though there is a greater risk of complications
and morbidity after bilateral submandibular duct ligation, compared to BoNT-A there was a
significantly greater and longer-lasting positive effect on most outcomes.
Drooling (sialorrhea), a prevalent problem (44%) in chil-
dren with non-progressive neurodevelopmental disabilities,
including cerebral palsy (CP),1 has a substantial impact on
the well-being and daily life of children and their care-
givers. Frequent wiping and changing of bibs and clothes
is required, while saliva damages perioral skin, clothes,
communication aids, furniture, and floors. Beyond the
physical implications, drooling may be a main source of
social and emotional distress and may have a negative
impact on self-esteem and participation in society, school
activities, and family life.2–4 Additionally, drooling may
lead to avoidance by others, social isolation, and an under-
estimation of mental capacities even though cognitive func-
tions are not necessarily impaired.2 Caregivers have
expressed concern about the risk of embarrassment, social
isolation, and stigmatization.3
When conservative treatment (oral motor or behavioural
therapy) are ineffective, anticholinergics, botulinum
neurotoxin A (BoNT-A), or surgery may be considered. In
our view, anticholinergics are currently only considered in
case of lack of effect or contraindications to surgery or
BoNT-A. While there is still a chance for patients to ‘out-
grow’ drooling, BoNT-A could be considered from the
age of 4 years onwards.5 Our saliva control team primarily
focuses on the submandibular glands for interventional
therapy since the submandibular glands are responsible for
70% of the total saliva production in the unstimulated
state. Combined injections (parotid and submandibular) are
only considered when there is no or inadequate response
to submandibular BoNT-A to prevent patients from being
overtreated when initially combining injections and to limit
related morbidity.6,7
Bilateral submandibular duct ligation was recently
described as a short and simple day treatment procedure
offering an alternative to BoNT-A and more invasive sur-
gery, such as submandibular duct relocation and
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submandibular gland extirpation.6,8 A recent randomized
controlled trial (RCT) from our research group showed
almost 90% treatment success in drooling reduction
8 weeks after bilateral submandibular duct ligation com-
pared to a treatment success of 54% 8 weeks after sub-
mandibular BoNT-A, which is only slightly lower than
treatment success after submandibular duct relocation and
submandibular gland extirpation.9–13 In that trial, treat-
ment success was defined as a 50% or more reduction in
drooling quotient and/or caregiver score on a visual ana-
logue scale. There was a slightly greater risk for complica-
tions and morbidity after bilateral submandibular duct
ligation compared to BoNT-A.6 The cost-effectiveness
analysis revealed that BoNT-A is less expensive per per-
centage of success than bilateral submandibular duct liga-
tion. However, the additional cost of bilateral
submandibular duct ligation over BoNT-A is offset by
greater treatment success. The cost of both procedures is
equal after approximately 1.5 BoNT-A injections.14 As part
of this RCT, additional information was collected on the
impact of drooling on well-being and daily care. The aim
of this article is to report the effect of BoNT-A and bilat-
eral submandibular duct ligation on drooling severity and
its impact on daily life and care, damage to electronic
devices and/or furniture, social interactions, and self-




This RCT was conducted at Radboud University Medical
Center Nijmegen, the Netherlands between April 2012
and August 2017. Patients were randomly allocated to
treatment with BoNT-A or bilateral submandibular duct
ligation. There was partial blinding for treatment alloca-
tion. Investigators measuring the objective outcomes were
masked, whereas patients and caregivers were not blinded
to treatment allocation. For a detailed description of the
study design, see Bekkers et al.6
Participants
Patients were recruited at the regular outpatient Saliva
Control clinic of Radboud University Medical Center
where these children and adolescents were assessed. The
multidisciplinary team included a paediatric neurologist, a
paediatric speech and language therapist, a rehabilitation
specialist, a psychologist, and an ear, nose, and throat sur-
geon on consultation. All eligible patients underwent oral
motor therapy to optimize swallowing and mouth closure
skills before inclusion. All children and adolescents whose
conservative treatment (speech and language or behavioural
therapy) had failed or was not expected to provide substan-
tial relief were considered for the study. Children were
aged 8 years or older (when there is a low chance that chil-
dren would still ‘outgrow’ drooling), diagnosed with CP or
any other non-progressive neurodevelopmental disorder,
and reported with moderate or severe drooling (defined as
a drooling frequency score ≥3 or drooling severity score
≥2).15
Interventions
Both BoNT-A injections and bilateral submandibular duct
ligation were performed in an outpatient setting. BoNT-A
(Allergan, Nieuwegein, the Netherlands) was administered
to the submandibular glands under general anaesthesia,
fractioning 25U in 0.9% saline over each submandibular
gland using a 25-gauge needle and ultrasound guidance.
Patients were treated under general anaesthesia and ultra-
sound guidance to decrease the risk of adverse events in
the case of extra-glandular BoNT-A. In participants with
previous BoNT-A treatment, BoNT-A injections or bilat-
eral submandibular duct ligation were performed at least 6
months after the last injection to prevent a carry-over
effect.
Bilateral submandibular duct ligation was also performed
under general anaesthesia. The submandibular ducts were
traced, dissected, and ligated, applying two metal vascular
clips to each duct. Intraoral absorbable sutures closed the
incision.6 All patients who had received bilateral sub-
mandibular duct ligation received amoxicillin/clavulanic
acid and paracetamol plus diclofenac for 7 and 5 days
respectively.
Outcome measures
A questionnaire was filled out by one of the parents or
caregivers (hereafter referred to as caregivers) at the base-
line measurement and 8 and 32 weeks posttreatment
(Appendix S1, online supporting information). Drooling
severity in 13 specific positions and daily activities (e.g. sit-
ting, eating, relaxing; Appendix S1) and the impact of
drooling on daily care, the child’s social interactions, and
self-esteem were scored by the caregivers in the question-
naire. Caregivers were also asked the average number of
times during the past 2 weeks they had to wipe the child’s
chin (per hour), encourage the child to swallow (per hour),
and change bibs (per day). Moreover, the questionnaire
included a question of whether damage to furniture and/or
electronic devices (communication aids, tablets, electronic
wheelchair) had occurred due to drooling during the past
2 weeks (dichotomous yes or no answer). The question-
naire was originally developed by our multidisciplinary sal-
iva control team to evaluate the effect of BoNT-A on the
impact of drooling and has been shown to be sensitive to
change over time.2,16–18 It contains multiple visual ana-
logue scales, several multiple choice questions, and some
open-ended questions.16
What this paper adds
• Bilateral botulinum neurotoxin A (BoNT-A) and submandibular duct ligation
had a positive effect on the well-being of individuals with moderate-to-
severe drooling.
• Bilateral submandibular duct ligation had a greater effect on the impact of
drooling during daily care than BoNT-A.
• Bilateral submandibular duct ligation reduced damage to electronic devices
and improved social interactions and satisfaction with life.
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Statistical analysis
All data were analysed using SPSS 22.0 for Windows
(IBM Corp., Armonk, NY, USA). Patients who crossed
over to the other treatment arm were analysed according
to the intention-to-treat principle. Patients who were
excluded or withdrew from the study were not included in
the analyses. Descriptive statistics were used to summarize
patient characteristics. Paired and unpaired sample t-tests
were used to compare normally distributed continuous
variables, such as bib or shawl replacements, while ordinal
level variables, including drooling severity, were compared
using Mann–Whitney U and Wilcoxon tests and nominal
level variables via v2 tests. Missing data were missing at
random and automatically imputed 20 times by SPSS; they
were stratified by treatment group, with all patient charac-
teristics and clinical outcomes as variables in the model.
Multiple imputation for missing data on the last three
questions regarding emotional reactions (questions 15–17)
were performed separately, excluding children with an
estimated developmental age of less than 4 years since
they were considered unable to express their feelings on
physical appearance and social acceptance.16,17 Drooling
severity in 13 positions and daily activities was analysed in
children able to participate in the displayed positions and
daily activities, excluding children to whom the position
or daily activity was not applicable. Differences in change
between interventions from baseline to 8 and 32 weeks
were evaluated using mixed-model analysis for the contin-
uous variables. Binary logistic regression was used to test
for differences between treatments within dichotomous
variables, with the intervention and baseline values as
independent variables. A p-value of ≤0.05 was considered
statistically significant and 95% confidence intervals (CIs)
were given for the interpretation of the point estimates
and significance levels.
Standard protocols, registrations, and patient consent
Approval of an independent regional ethics committee
(Commissie Mensgebonden Onderzoek regio Arnhem –
Nijmegen) and registration in the Dutch Trial Register
(Netherlands Trial Register identifier: NTR3537) was
obtained. Written and informed consent by caregivers or
patients was provided for all participants.
Role of study sponsors
The study sponsors had no influence on the study design,
collection of data, data analysis, interpretation of data,
writing of the report, or decision to submit the paper for
publication.
RESULTS
Of the 119 participants who were screened for eligibility,
40 did not meet the inclusion criteria and 22 declined par-
ticipation, leaving 57 children and adolescents randomized
to treatment allocation (Fig. S1, online supporting infor-
mation). Fifty-three participants (31 males, 22 females,
mean age 11y, range 8–22y, SD 2y 10mo) were analysed.
Three children did not receive the allocated intervention
and one child crossed over to the BoNT-A arm because
their caregivers preferred BoNT-A to bilateral sub-
mandibular duct ligation. Thirty-one children were diag-
nosed with CP, while 22 children had other unexplained
neurodevelopmental disabilities mainly based on a syn-
drome (Pitt–Hopkins, cri du chat, distal 18q, Sj€ogren-
Larsson, Marden–Walker, ATR-X), genetic (deletions or
trisomy), or metabolic (mitochondrial) disorder. Baseline
assessments were obtained at an average of 18 weeks (SD
15wks) before intervention. Four children were previously
treated with anticholinergics, which were stopped due to
adverse events or lack of effect. Patient characteristics and
the number of preceding submandibular BoNT-A injec-
tions did not differ significantly between the BoNT-A and
bilateral submandibular duct ligation group (Table 1).6
Drooling severity
Caregivers marked the severity of drooling in 13 positions
and daily activities as not applicable (99), none (1), mild
(2), moderate (3), severe (4), or very severe (5). For some
participants, positions and daily activities were not applica-
ble in supported sitting (BoNT-A=1; bilateral submandibu-
lar duct ligation=1), unsupported sitting (BoNT-A=1;
bilateral submandibular duct ligation=3), prone position
(BoNT-A=5; bilateral submandibular duct ligation=5),
walking (BoNT-A=9; bilateral submandibular duct liga-
tion=12), intensive movements (BoNT-A=7; bilateral sub-
mandibular duct ligation=7), tired (BoNT-A=0; bilateral
submandibular duct ligation=0), eating (BoNT-A=4; bilat-
eral submandibular duct ligation=3), drinking (BoNT-A=4;
bilateral submandibular duct ligation=5), talking (BoNT-
A=9; bilateral submandibular duct ligation=8), concen-
trated activity (BoNT-A=3; bilateral submandibular duct
ligation=2), relaxed, watching TV (BoNT-A=2; bilateral
submandibular duct ligation=1), strenuous activity (BoNT-
A=1; bilateral submandibular duct ligation=1), and enthusi-
astic (BoNT-A=0; bilateral submandibular duct ligation=0)
respectively. Excessive drooling (i.e. severe or very severe
drooling) at baseline was most common in a prone position
(89%) or during intensive movement (sport) (83%) and
least reported during talking (49%) or drinking (53%).
Eight weeks after BoNT-A and bilateral submandibular
duct ligation, caregivers reported reduced drooling in all
positions and daily activities (Fig. 1). Thirty-two weeks
after treatment, the degree of drooling remained decreased
in all positions and daily activities for the bilateral sub-
mandibular duct ligation group (p<0.001) except for walk-
ing, in contrast to children who underwent BoNT-A,
whose drooling severity had not significantly decreased
during walking, intensive movements, or eating and even
significantly increased during drinking, talking, and strenu-
ous activity compared to baseline as illustrated by Figure 1.
The mean percentage of excessive drooling from all 13
positions and daily activities together dropped from 74%
to 46% 8 weeks after BoNT-A (mean difference=28.2,
p<0.001, 95% CI 19.4–37.1) but increased again to 66%
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32 weeks after BoNT-A (mean difference from base-
line=7.6, p=0.009, 95% CI 2.3–13.0). For bilateral sub-
mandibular duct ligation, the mean percentage of excessive
drooling from all 13 positions and daily activities together
declined from 71% at baseline to 15% after 8 weeks (mean
difference=55.6, p<0.001, 95% CI 46.0–65.3), which
increased to 34% 32 weeks posttreatment (mean difference
from baseline=37.4, p<0.001, 95% CI 31.1–43.7). At both
8 and 32 weeks, bilateral submandibular duct ligation had
a greater effect on mean excessive drooling reduction than
BoNT-A with a mean difference of 27.4 (p<0.001, 95%
CI 39.8 to 15.0) and 29.8 (p<0.001, 95% CI 37.7 to
21.9) respectively.
Daily care
Baseline values for BoNT-A and bilateral submandibular
duct ligation were equal (p>0.05) in all three conditions.
Both BoNT-A and bilateral submandibular duct ligation
decreased the amount of hourly wiping after 8 and
32 weeks but bilateral submandibular duct ligation had a
greater effect than BoNT-A at follow-up (mean differ-
ence=4.1, F[1,51]=8.660, p=0.002; 95% CI 1.5–6.7;
Fig. 2).
The caregivers of children treated with BoNT-A
encouraged their children to swallow a mean of 2.3 times
per hour at baseline. Hourly encouragement to swallow
decreased non-significantly to 1.8 times per hour after
8 weeks (p=0.44, 95% CI 0.8 to 1.8) and showed no fur-
ther change from 8 to 32 weeks (p=0.96, 95% CI 1.1 to
1.0). After bilateral submandibular duct ligation, the hourly
encouragement to swallow decreased from 3.6 to 1.6
(p=0.009, 95% CI 0.5–3.6) at 8 weeks and to 1.7 per hour
(p=0.027, 95% CI 0.2–3.6) after 32 weeks, which was not
significantly different from BoNT-A (mean differ-
ence=0.17, F[1,51]=0.267 p=0.655; 95% CI 0.6 to 0.9;
Fig. 2).
Bilateral submandibular duct ligation reduced the mean
number of bib or shawl changes for the collection of saliva
from 6 to 4.2 times a day after 8 weeks (p=0.05, 95% CI
0.0–3.5) and to three times a day 32 weeks after treatment
(p=0.039, 95% CI 0.2–5.7). BoNT-A did not significantly
change the mean number of bib or shawl changes after 8
and 32 weeks. The difference in reduction induced by
bilateral submandibular duct ligation compared to BoNT-
A was not significant (mean difference=0.63, F[1,51]
=0.411, p=0.516; 95% CI 1.3 to 2.5).
Table 1: Baseline demographic and clinical characteristics of the intention-to-treat population
BoNT-A (n=26)
Bilateral submandibular
duct ligation (n=27) p
Age, y:mo, mean (SD) 11:2 (2:6) 11:1 (3:2) 0.93
Female sex 11 (42.3) 11 (40.7) 0.91
Main diagnosis
Spastic CP 10 (38.5) 6 (22.2) 0.46
Dyskinetic CP 1 (3.8) 3 (11.1)
Spastic/dyskinetic CP 5 (19.2) 5 (18.5)
CP type missing 1 (3.8) 0
Other non-progressive neurodevelopmental disordera 9 (34.6) 13 (48.1)
GMFCS levelb (n=31) n=17 n=14 0.33
II 2 (11.8) 1 (7.1)
III 3 (17.6) 0
IV 5 (29.4) 8 (57.1)
V 7 (41.2) 5 (35.7)
Mobility
Ambulant 11 (42.3) 10 (37) 0.70
Non-ambulant 15 (57.7) 17 (63)
Estimated developmental age
<4y 15 (57.7) 15 (55.6) 0.88
≥4y 11 (42.3) 12 (44.4)
Epilepsy
Yes 17 (65.4) 15 (55.6) 0.47
Controlled 13 (76.5) 13 (86.7) 0.66
Intractable 4 (23.5) 2 (13.3)
No 9 (34.6) 12 (44.4)
Gastrostomy feeding
Oral 16 (61.5) 20 (74.1) 0.33
Gastrostomy/gastrostomy and oral (no pharyngeal swallowing
problem)
10 (38.5) 7 (25.9)
Underwent BoNT-A pre-trial
No 11 (42.3) 10 (37) 0.70
Yes 15 (57.7) 17 (63)
Number of received submandibular BoNT-A injections, mean (SD) 1.6 (1.8) 1.4 (1.3) 0.19
Time since last BoNT-A injection, y:mo, mean (SD) 1:1 (0:8) 2:0 (2:10) 0.26
Data are n (%) unless otherwise stated. BoNT-A, botulinum neurotoxin A; CP, cerebral palsy; GMFCS, Gross Motor Function Classification
System. aDisorders mainly based on a syndrome (Pitt–Hopkins, cri-du-chat, distal 18q, Sj€ogren–Larsson, Marden–Walker, ATR-X), genetic
(deletions or trisomy), or metabolic (mitochondrial) disorder. bOnly applicable in children with CP (n=31). GMFCS levels I to III, ambulant;
GMFCS IV and V, non-ambulant. p<0.05 was considered statistically significant.
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Damage to electronic devices and/or furniture
Damage to communication aids, electronic communication
devices, computers, tablets, and/or audio equipment caused
by drooling was reported by 23% (6 of 26) of caregivers
before BoNT-A administration. Eight weeks after, this rate
dropped to 19% (5 of 26) while 32 weeks after injection
39% (10 of 26) of caregivers reported damage. The care-
givers of children treated with bilateral submandibular duct
ligation noticed a significant reduction in damage to elec-
tronic devices from 30% (8 of 27) at baseline to 11% (3 of
27) 8 weeks after surgery, which remained 11% 32 weeks
after treatment. The difference in damage reduction com-
pared to BoNT-A was statistically significant after
32 weeks (p=0.032, B=1.77, 95% CI 1.2–29.7).
Drooling causing damage to floors and/or furniture was
reported by 27% (7 of 26) of caregivers before BoNT-A
treatment, which diminished to 19% (5 of 26) and 12% (3
of 26) after 8 and 32 weeks respectively. Damage to floors
and/or furniture due to drooling in children assigned to
bilateral submandibular duct ligation was reported by 15%
(4 of 27) of caregivers at baseline. Eight weeks after sur-
gery, no caregivers reported any damage to floors and/or
furniture, while after 32 weeks this rate had risen to 11%
(3 of 27). A significant difference between the effect of
BoNT-A and bilateral submandibular duct ligation on
damage to floors and/or furniture was not found.
Social interactions
Drooling appeared to have a negative impact on social
interactions as illustrated in Table 2. Both treatments had
a positive, yet non-significant influence on social interac-
tions at 8 and 32 weeks after treatment. The impression of
caregivers of the child’s satisfaction with their social con-

























































































Figure 1: Median reduction in drooling severity 8 and 32 weeks after treatment. *Statistical significance between baseline and 8-weeks follow-up
(p<0.05); **statistical significance between baseline and 32-weeks follow-up (p<0.05). BoNT-A, botulinum neurotoxin A.
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the past 4 weeks improved but did not show a significant
difference. The child’s satisfaction with their relationships
within the family as perceived by their caregivers improved
by 17.6 points (mean difference=17.6, p<0.001, 95% CI
9.0–26.2) 8 weeks after bilateral submandibular duct liga-
tion and by 10.5 points 32 weeks after bilateral sub-
mandibular duct ligation (mean difference=10.5, p=0.015,
95% CI 1.9 to 0.2). Likewise, the child’s satisfaction
with life in general improved after bilateral submandibular
duct ligation by 17.6 (mean difference=17.6, p<0.001, 95%
CI 9.7–25.6) and 12.5 (p=0.003, 95% CI 4.2–20.7) points
respectively on the 0 to 100 visual analogue scale after 8
and 32 weeks. After BoNT-A, there was no significant
improvement at either 8 or 32 weeks. A significant differ-
ence between bilateral submandibular duct ligation and
BoNT-A was not found.
Self-esteem
To obtain an impression of the occurrence and change in
emotional reactions, caregivers were asked whether their
child overtly expressed any positive and/or negative feel-
ings about their physical appearance and social acceptance
by peers and adults. Eleven children treated with BoNT-A
and 12 children in the bilateral submandibular duct liga-
tion group had an estimated developmental age >4 years
and were analysed. Overtly negative reactions about physi-
cal appearance because of drooling were expressed by 27%
(3 of 11) of children and adolescents before BoNT-A and
by 8% (1 of 12) before bilateral submandibular duct liga-
tion. Both BoNT-A and bilateral submandibular duct liga-
tion reduced this to 0% at the 32-week follow-up. Similar
results were achieved regarding acceptance by adults; 26%









































































Figure 2: The impact of drooling on daily care. Botulinum neurotoxin A (BoNT-A) (n=26); bilateral submandibular duct ligation (n=27). (a) Mouth or chin
wiped dry. (b) Encouraged to swallow. (c) Bib or shawl replacement. *Statistical significance (p<0.05) between baseline and follow-up; **statistical sig-
nificance between BoNT-A and bilateral submandibular duct ligation (p<0.05).
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reactions because of drooling at baseline for BoNT-A and
bilateral submandibular duct ligation respectively. At the
32-week follow-up, children and adolescents did not
express any negative reactions because of drooling in both
treatment arms. Negative reactions (caused by drooling) by
peers were present in 16% of children before BoNT-A and
in 18% of children before bilateral submandibular duct
ligation. After 32 weeks, this was 30% in the children and
adolescents treated with BoNT-A and 0% after bilateral
submandibular duct ligation. Statistical analyses regarding
emotional reactions were not performed due to the rela-
tively limited numbers.
Adverse events and postoperative complaints
There were more adverse events after bilateral sub-
mandibular duct ligation than BoNT-A (40.7% vs 19.2%).
The total number of days with postoperative issues was
significantly greater after bilateral submandibular duct liga-
tion compared to BoNT-A (9.6d vs 3.9d).6
DISCUSSION
This RCT aimed to evaluate and compare the effect of
BoNT-A and bilateral submandibular duct ligation on
drooling severity in 13 specific positions and daily activities
and the impact of drooling on well-being in children and
adolescents with neurodevelopmental disorders. Both
BoNT-A and bilateral submandibular duct ligation had a
positive effect on drooling severity, reducing daily care,
decreasing material damage to floors and/or furniture, and
improving social interactions. However, submandibular
duct ligation was significantly more effective in reducing
drooling in the short- (8wks) and medium-term (32wks),
making daily care less demanding by reducing the amount
of hourly saliva wiping and reducing damage to electronic
devices when compared to BoNT-A. Additionally, bilateral
submandibular duct ligation – in contrast to BoNT-A –
improved the child’s satisfaction regarding their relation-
ships within the family and with life in general, having a
significantly higher impact on these aspects of well-being
in these children and their caregivers.
The reduced effect of BoNT-A injections after 32 weeks
was expected since it naturally lasts for a median of
22 weeks.4,7,19 However, a prolonged effect of BoNT-A on
several domains, although not significant, was experienced
at 32 weeks by several participants, which is in line with
the observation of a continued effect by Scheffer et al.19 up
to 1 year after injection in a handful of children. Despite
this prolonged effect in some participants and the expected
effect of BoNT-A at 8 weeks, bilateral submandibular duct
ligation had a higher impact on several aspects of well-
being in both the short- and medium-term.
Even though both BoNT-A and bilateral submandibular
duct ligation were effective in reducing drooling,6–8,19,20
the question remains as to how to define a clinically rele-
vant outcome since occasional drooling may still be stig-
matizing and burdensome. To many patients and
caregivers, the effect of treatment is determined by a
reduction in drooling frequency and severity, changes in
how it impacts daily life and care, and improvement in
well-being and quality of life.21 To our knowledge, these
factors have not been combined in a randomized con-
trolled setting for BoNT-A and bilateral submandibular
duct ligation before.
The effect of BoNT-A and bilateral submandibular duct
ligation on the impact of drooling corresponds to a previ-
ously published objective effect in this RCT where both
treatments were effective but response to treatment after
bilateral submandibular duct ligation was higher after 8
(mean difference=35.1%, 95% CI 23.6–46.6) and 32 weeks
(mean difference=36.1%, 95% CI 18.1–54.1) than the
response to BoNT-A.6 Although both treatments improved
the well-being of these children, this study, like others,
also confirmed some loss of gain between 8 and 32 weeks
after both bilateral submandibular duct ligation and
BoNT-A.6,22–24 Additionally, it highlighted more adverse
events and significantly more complaints after bilateral
submandibular duct ligation compared to BoNT-A.6 The
slightly greater risk for complications and morbidity seen
after bilateral submandibular duct ligation did not out-
weigh the impact on the well-being of these children since
there were higher scores on most aspects of the question-
naire after bilateral submandibular duct ligation. This
might be explained by the relatively mild and temporary
complications and adverse events after bilateral
Table 2: The social consequences of drooling
BoNT-A (n=26) Bilateral submandibular duct ligation (n=27)
Baseline 8 weeks 32 weeks Baseline 8 weeks 32 weeks
Avoided by other children
Yes 14 (54.8) 11 (41.9) 10 (36.3) 15 (56.9) 8 (29.8) 11 (42.0)
Yes, main reason drooling 12 (82.5) 6 (58.7) 7 (76.2) 11 (72.0) 1 (14.9) 8 (66.5)
Avoided by adults
Yes 8 (31.2) 5 (20.8) 8 (32.1) 10 (38.5) 6 (21.7) 9 (32.4)
Yes, main reason drooling 6 (71.6) 5 (100) 6 (76.0) 8 (73.1) 2 (40.2) 5 (52.6)
Underestimation of mental ability
Yes 13 (50.6) 13 (51.5) 13 (48.1) 12 (45.7) 12 (43.1) 11 (40.2)
Yes, main reason drooling 5 (37.3) 6 (43.7) 6 (50.4) 7 (58.7) 3 (26.6) 5 (43.3)
Data are n (%). BoNT-A, botulinum neurotoxin A.
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submandibular duct ligation. Namely, there were no long-
lasting inconveniences; all adverse events lasted <6 weeks,
complaints lasted for a mean of 10 days (range 1–14d, SD
3.9d) post-bilateral submandibular duct ligation, and there
was no indication for surgical reintervention.
Previous studies used the Drooling Impact Scale (DIS)
to evaluate drooling-related quality of life after BoNT-
A.25,26 The DIS is a validated quality of life questionnaire
for drooling. Reid et al.25 reported a reduction in drooling
(27.5, p<0.001) and improvement in quality of life in
children 1 month after salivary gland BoNT-A injections
(n=24) compared to children in a control group (n=23),
which corresponds to the findings in this article. Chanu
et al.27 assessed the benefit in quality of life with the Glas-
gow Children’s Benefit Inventory 3 months after combined
submandibular and parotid duct ligation.27 In this study, a
mean Glasgow Children’s Benefit Inventory score of
+36.15 on a scale from 100 (maximum harm) to +100
(maximum benefit) was recorded. Even though this general
scale did not specifically address the consequences of
drooling, diminished drooling was shown to have a major
impact on general well-being. However, the improvement
in well-being is in line with the findings in the current
study.
The data on the effect of BoNT-A and bilateral sub-
mandibular duct ligation on the impact of well-being in
children with severe drooling collected prospectively in a
randomized controlled setting are a major strength of this
study. However, there are some potential limitations that
need to be addressed. First, there were missing question-
naires and values that might potentially lead to biased
results. Multiple imputation was used to adjust for any
influencing factors. Second, the questionnaire used in the
current study was not validated, unlike the DIS, which was
introduced in 2010.25 However, previous research has pro-
ven the questionnaire to be sensitive to change over time,
which was the main interest in this study.2,16–18 Besides,
unlike the DIS, the questionnaire also evaluates social and
emotional consequences in more detail and quantifies the
severity of drooling in multiple positions and daily activi-
ties. Nonetheless, having at least a baseline DIS to com-
pare the results to other studies would have improved the
current study. Future research should validate the ques-
tionnaire used in the current study and assess inter- and
intra-responder variability. Third, despite randomization,
baseline drooling in several positions and daily activities
was not equal between the BoNT-A and bilateral sub-
mandibular duct ligation groups. During supported sitting,
unsupported sitting, concentrated activity, and strenuous
activity, the mean percentage of excessive drooling was sig-
nificantly higher in children treated with BoNT-A. How-
ever, the mean decrease in drooling severity from baseline
to 32 weeks after treatment was significantly higher in chil-
dren treated with bilateral submandibular duct ligation
compared to those treated with BoNT-A in all positions
and daily activities, suggesting no major influence of the
unequal baseline values.
Another limitation of this study is the fact that question-
naires were filled out before inclusion, possibly leading to
an exaggeration of complaints to receive treatment.
Although wiping and encouragement to swallow might be
non-specific for the degree of drooling, both outcomes
were included because we felt that they gave an insight
into perceived daily care. Moreover, there was no blinding
for treatment allocation for patients and caregivers since
sham surgery is considered unethical; this may have led to
assessment bias in caregivers favouring one of the two
treatments.
Future research should consider using a cross-over
design to compare treatment within participants, where
patients would receive surgery after BoNT-A. Additionally,
the questionnaires were not always filled out by the same
caregiver. The limited follow-up time is another limitation
since reduction in drooling and impact on daily life after
bilateral submandibular duct ligation seemed to fade
slightly from 8 to 32 weeks of follow-up. Future research
should determine the specific long-term effects of bilateral
submandibular duct ligation, drooling-related well-being,
and quality of life in a larger patient population.
CONCLUSION
Previous literature illustrated that bilateral submandibular
duct ligation is a more effective treatment for drooling
than BoNT-A but carries a slightly greater risk of compli-
cations and morbidity.5 This RCT demonstrated a positive
effect on the well-being of children, adolescents, and their
caregivers through a reduction in drooling severity, daily
care, an improvement in social interactions, and higher
self-esteem by both BoNT-A and bilateral submandibular
duct ligation. Even though there is a greater risk of com-
plications and morbidity after bilateral submandibular duct
ligation, it is significantly more effective than BoNT-A
with regard to reducing the amount of daily care; damage
to electronic devices, floors, and/or furniture; and positive
changes in social interactions.
Therefore, bilateral submandibular duct ligation could
be considered when, for various reasons, BoNT-A is no
longer preferred and when submandibular gland extirpa-
tion or submandibular duct relocation are rejected or con-
traindicated. In our clinic, systemic anticholinergics are
currently only considered in case of an unsatisfactory result
from or contraindications to BoNT-A or surgery. Future
research should focus on the cost-effectiveness, long-term
effect on drooling severity, and related impact of bilateral
submandibular duct ligation compared with alternative sur-
gery to determine the role of bilateral submandibular duct
ligation in current drooling treatment strategies.
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